14 results about "Intracellular bacterium" patented technology

The invention discloses a DC (dendritic cell) capture type engineering bacterial vaccine for realizing cytoplasm antigen transfer by utilizing gap connection, which is characterized in that attenuated salmonella VNP20009 is utilized to simultaneously express Antigen 4T1-M8 and DC capture peptide CBP-12 to increase contact so as to enhance formation of gap connection between tumor cells and DC and promote delivery of antigen to DC cytoplasm, so that MHC-I mediated cross presentation is enhanced. In addition, as an intracellular bacterium, the VNP20009 can infect tumor cells and colonize in the tumor cells. Therefore, the tumor antigen carried by the VNP20009 can be expressed in cells, so that the tumor antigen can be presented to the surfaces of tumor cells by MHC-I as an endogenous antigen to be recognized by specific CD8 + T cells.

The present invention provides nanoparticles for targeted elimination of intracellular bacteria and a preparation method thereof. The nanoparticles are composed of a biodegradable nanoparticle matrix, a potassium ion-responsive linear polymer grafted onto the surface of the nanoparticle matrix, and a drug loaded into the pore structure of the nanoparticle matrix. The nanoparticle matrix has a pore structure, the drug is a drug for treating bacterial infection, and the potassium ion-responsive linear polymer can achieve conformational transition and charge reversal after recognizing and responding to potassium ions. The nanoparticles are taken into the cells through the endocytosis of macrophages. In the high potassium ion concentration environment within the cells, the potassium ion-responsive linear polymer on the surface of the nanoparticles complexes with potassium ions, causing the nanoparticles, which are negatively charged in the extracellular fluid, to undergo charge reversal within the cells, thereby inducing the nanoparticles to target and bind to the intracellular bacteria, while simultaneously undergoing conformational transition and releasing the loaded drug.

This invention is directed to methods of reducing incidence or reducing severity or preventing progression of or preventing or treating or preventing pathogenesis of a cancer in a subject, wherein said subject is predisposed to, showing early indications of or suffering from cancer, or methods of reducing intracellular bacterial infection in subjects at risk for or suffering from carcinoma, or from pre-neoplastic or metaplastic tissue changes, comprising contacting at least one cell in an affected tissue in said subject with an agent reducing intracellular bacterial infection in affected tissue, reducing localization of intracellular bacteria proximally to nuclei in cells of affected tissue, or a combination thereof. This invention is further directed to methods of personalized optimized diagnosis and therapy in a subject, comprising screening a subject predisposed to, or at risk for cancer and identifying whether the pre-cancerous or cancerous tissue in the subject is intracellularly infected with bacteria, optionally assessing the intracellular localization of the bacteria-containing compartment to determine a distance of same from a nucleus in the cell; optionally assessing the oncogene profile expression in the subject, and further scoring the subject in terms of the prognosis and potential for therapy and then treating the subject to reduce the intracellular bacterial burden, promote re-localization of the bacterial compartment to be at a further distance from the nucleus, successfully eradicate intracellular bacterial infection, prevent or reduce cell-to-cell spread of the bacteria or any combination thereof. Compositions and kits for effecting the methods of this invention are also provided. This invention still further provides a system for identifying patients who would benefit from adjunctive antimicrobial therapies, enhancing treatment outcomes by providing comprehensive microbial feature characterization, including spatial localization of key microbes associated with treatment resistance in an integrated platform with advanced machine learning algorithms, ultimately providing a personalized patient assessment, enhancing treatment outcomes and optimizing therapeutic strategies.

The application provides a double-strand DNA vaccine for late Edwardsiella tarda disease, which can significantly induce Th1 type immune bias, enhance fish cell immune response, improve the resistance to intracellular bacterial infection, and has the advantages of safety and high efficiency, easy preparation, strong adaptability for on-site promotion and the like. The double-strand DNA vaccine uses a fusion fragment of an immune adjuvant IL-12, which is constructed by connecting a nucleic acid fragment coding a subunit 12p35 with an amino acid sequence of SEQ ID NO:1 and a nucleic acid fragment coding a subunit 12p40 with an amino acid sequence of SEQ ID NO:3 through a flexible connecting peptide linker. The double-strand DNA vaccine realizes the synergistic expression of OmpC antigen and IL-12 adjuvant, enhances immunogenicity, and solves the problem of insufficient immune effect of a traditional DNA vaccine; and the vaccine has no obvious toxic side effect on fish bodies, is not dependent on the use of antibiotics, is green and environmentally friendly, and has a good industrialization prospect.

The application belongs to the technical field of microorganism detection, and discloses a method for extracting intracellular bacteria of ameba in a water environment and environmental application; the method comprises the following steps: S1, filtering a water environment sample and ameba enrichment culture; S2, removing extracellular bacteria attached to ameba by coupling treatment of a chelating agent and lysozyme; S3, releasing intracellular bacteria by lysing ameba by using a lysing agent in combination with mechanical suction; and S4, centrifugation and filtration purification to obtain pure intracellular bacteria; the application is simple in operation, low in cost, high in bacterial purity, and can be used for water environment microorganism detection, drinking water safety monitoring, and provides technical support for ameba and intracellular bacteria interaction research.

The invention relates to biotechnology, in particular, to a method for producing an enzymatic lysate of biomass of methane-oxidizing bacteria, the method comprising enzymatic hydrolysis of a bacterial suspension using an enzyme preparation, which is derived from a pancreas, and / or pancreatin obtained from cattle or pigs, in amount of from 5000 to 7000 units of proteolytic activity per 1 kg of absolutely dry substance of the biomass of bacteria, at pH of from 7 to 8.5 and a temperature of 45°C to 55°C for from 4 to 12 hours. The invention also relates to a product obtained by said method. The resulting product has a high content of short-chain peptides with a molecular weight of from 150 to 1000 Da and can be used to produce feed additives and biologically active food supplements. The invention provides for an increase in bioavailability of intracellular bacterial components.

The invention discloses a mechanical phenotype analysis chip for screening bacterial infected circulating tumor cells, and belongs to application of a micro-fluidic chip technology in the field of biomedical in-vitro diagnosis. The system comprises a micro-fluidic chip and a detection solution. The micro-fluidic chip comprises a sample introduction end, a shunting flow channel, a main flow channel and a sample discharge end, wherein single-cell mechanical property analysis function unit arrays are uniformly distributed on the two sides of the main flow channel in a staggered manner; and the single cell mechanical property analysis functional unit comprises a hook-shaped structure for single cell anchoring and a deformation channel structure for single cell mechanical property analysis. The detection solution comprises a fluorescent probe capable of specifically recognizing bacteria in cells. According to the micro-fluidic chip disclosed by the invention, single cell capture, mechanical property analysis and intracellular bacteria detection can be integrated on the same chip, and a time-saving, low-cost and high-throughput single cell detection platform can be constructed, so that visual detection of single cell mechanical phenotypes and intracellular bacteria is realized; the method can be used for evaluating the metastasis potential of the circulating tumor cells in the bacterial infection breast cancer.

According to the bicistronic DNA vaccine for edwardsiella tarda disease of paralichthys olivaceus, provided by the invention, the bicistronic DNA vaccine can remarkably induce Th1 type immune bias, enhance immune response of fish cells and improve the resistance to intracellular bacterial infection, and has the advantages of being safe, efficient, easy to prepare, high in field popularization adaptability and the like. A fusion fragment of an immunologic adjuvant IL-12 is used in the bicistronic DNA vaccine, and the bicistronic DNA vaccine is constructed by connecting a nucleic acid fragment of a subunit 12p35 of which the coding amino acid sequence is SEQ ID NO: 1 and a nucleic acid fragment of a subunit 12p40 of which the coding amino acid sequence is SEQ ID NO: 3 through a flexible connecting peptide joint. According to the bicistronic DNA vaccine disclosed by the invention, the synergistic expression of the OmpC antigen and the IL-12 adjuvant is realized, the immunogenicity is enhanced, and the problem of insufficient immune effect of the traditional DNA vaccine is solved; and the vaccine has no obvious toxic or side effect on the fish body, does not depend on antibiotics, is green and environment-friendly, and has a good industrialization prospect.

This invention discloses broad-spectrum antibacterial peptides WP-4 and WP-6, their compositions, and applications, belonging to the fields of antimicrobial peptide technology and biomedicine. This invention obtains a series of antimicrobial peptides by truncating and rationally modifying template peptides to balance the relationship between charge number, hydrophobicity, and amphiphilicity. By measuring antibacterial activity, stability, hemolytic activity, and cytotoxicity, two novel antimicrobial peptides, WP-4 and WP-6, with high activity and low toxicity were obtained, and their amino acid sequences are shown in SEQ ID NO. 5 and SEQ ID NO. 7. The novel antimicrobial peptides obtained by this invention possess broad-spectrum antibacterial activity, good stability under temperature, pH, salt ion, pepsin, and serum conditions, and exhibit no significant hemolytic activity and low cytotoxicity. They are characterized by rapid bactericidal action and low likelihood of inducing drug resistance. Furthermore, the antimicrobial peptides of this invention can enter cells and have a strong inhibitory effect on intracellular bacteria, showing broad application prospects.

The invention discloses a detection method of eukaryotic single cells and bacteria carried by the eukaryotic single cells and application of the detection method. The detection method comprises the following steps: providing pretreated eukaryotic single cells and bacteria carried by the eukaryotic single cells; providing a multiple reverse transcription primer system, and carrying out reverse transcription reaction on the multiple reverse transcription primer system, the pretreated eukaryotic single cell and the bacteria carried by the eukaryotic single cell to obtain a reverse transcription product; providing a microbead which is provided with a cell label, mixing the microbead with the reverse transcription product, and carrying out a ligation reaction so as to label the cell label on the reverse transcription product, thereby obtaining a ligation product; performing library construction on the connection product to obtain a single cell transcriptome library and a 16S rRNA library, and sequencing to obtain interaction information between eukaryotic single cells and bacteria carried by the eukaryotic single cells; host cell RNA and intracellular bacteria rRNA are subjected to efficient reverse transcription through a multiple reverse transcription primer system, and a host single cell transcriptome library and a 16S variable region library are constructed respectively, so that simultaneous detection of host cells and intracellular bacteria is realized.

The invention relates to the technical field of biological medicines, in particular to a nano-drug for removing intracellular bacteria as well as a preparation method and application of the nano-drug. The nano-drug is composed of hollow mesoporous nano-particles, an antibacterial drug loaded in the hollow mesoporous nano-particles, metabolism activation molecules grafted on the surfaces of the particles, and an immune cell fusion membrane coated on the outermost layer and pre-stimulated by inactivated bacteria. Through a synergistic effect mechanism of metabolism activation, targeted sterilization and immune awakening, the technical problems of intracellular bacterial metabolism dormancy, low drug targeted delivery efficiency and host immunosuppression microenvironment which are difficult to overcome in the prior art are effectively solved. Experiments show that the nano-drug can specifically target an infected part, reverse a bacterial metabolism dormancy state and synchronously realize efficient sterilization and immune activation, shows an excellent clearing effect in treatment of intracellular infection caused by staphylococcus aureus and the like, and can effectively establish lasting immune memory and remarkably reduce the infection recurrence rate.

The subject matter described herein is directed to tolfenpyrad derivatives of Formula I, or pharmaceutically acceptable salts thereof, which exhibit antibacterial activity against Francisella species with little to no toxicity to mammalian cells. Pharmaceutical compositions of tolfenpyrad derivatives, and methods of treating disorders associated with Gram-negative intracellular bacterial pathogens, such as Francisella tularensis, are also described.

CFU-less assays of quantifying intracellular bacteria and methods of using the CFU-less assays to identify host-targeting modulators of pathogen uptake or killing by host cells are described. Also described are host-targeting modulators of pathogen uptake by host cells and methods of using the host-targeting modulators to treat infection

The present invention relates to a method and composition for prevention and treatment of infections in a subject, in particular, with intracellular bacteria. The invention provides an optimized intracellular delivery of an active agent, in particular, a nucleic acid, using a nanoparticle formulation including an iNKT cell agonist.